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Abstract
 Objective—To evaluate the effect of early integrated, late integrated and delayed antiretroviral 
therapy (ART) initiation during tuberculosis (TB) treatment on incidence rates of loss to follow-up 
(LTFU) and to evaluate the effect of ART initiation on LTFU rates within trial arms in patients co-
infected with TB and HIV.
 Methods—A sub-study within a three-armed open label, randomised, controlled trial. Patients 
were randomised to initiate ART either early or late during TB treatment or after the TB treatment 
completion. We reported incidence and predictors of LTFU from TB treatment initiation during the 
24 months of follow-up. LTFU was defined as having missed 4 consecutive monthly visits with 
inability to make contact.
 Results—Of the 642 patients randomised, a total of 96 (15.0%) were LTFU at a median of 6.0 
(interquartile range (IQR): 1.1 to 11.3) months after TB treatment initiation. Incidence rates of 
LTFU was 7.5 per 100 person-years (py) (95% confidence interval (CI), 4.9 to 11), 10.9 per 100 
py (95% CI, 7.6 to 15.1) and 11.0 per 100 py (95% CI, 7.6 to 15.4) in the early integrated, late 
integrated and delayed treatment arm (p=0.313). Incidence rate of LTFU before and after ART 
initiation was 31.7 per 100 py (95% CI, 11.6 to 69.0) vs. 6.1 per 100 py (95% CI, 3.7 to 9.4), 
incidence rate ratio (IRR): 5.2 (95% CI, 2.1 to 13.0), p<0.001 in the early integrated arm; 31.9 per 
100 py (95% CI, 20.4 to 47.5) vs. 4.7 per 10 py (95% CI: 2.4 to 8.2), IRR: 6.8 (95% CI, 3.4 to 
13.6), p<0.0001 in the late integrated arm and 21.9 per 100 py (95% CI, 14.6 to 31.5) vs. 2.8 per 
100 py (95% CI, 0.9 to 6.6), IRR: 7.7 (95% CI, 3.0 to 19.9), p<0.0001 in the sequential arm.
 Conclusion—LTFU rates were not significantly different between the three trials arms. 
However, ART initiation within each trial arm resulted in a significant reduction in LTFU rates 
among TB patients.
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 INTRODUCTION
Tuberculosis (TB) remains a major cause of morbidity and mortality among people living 
with human immunodeficiency virus (HIV). 1 Almost 78% of TB-HIV co-infected patients 
reside in sub-Saharan Africa. 2 Loss to follow-up (LTFU) in both TB and antiretroviral 
therapy (ART) programmes remains a challenge globally, and more especially in sub-
Saharan Africa, where patients present late for care with advanced clinical diseases 3,4 and 
very low CD4+ counts. 5,6 LTFU often masks adverse clinical outcomes such as death and 
hospitalisation due to poor access to health care, but may also reflect the fact that the local 
patient population is highly mobile, as they often move between urban and rural homes. 7
While TB therapy and ART saves lives, 8 continuous success depends on regular clinic visits 
to ensure that viral suppression is sustained and monitor TB adherence until cure or therapy 
success is achieved. Published data show higher LTFU rates compared to mortality rates in 
ART programmes in sub-Saharan Africa where the largest contributor of attrition in ART 
programmes was LTFU at 56% followed by death at 40%. 9 In sub-Saharan Africa, we find 
retention rates of 49% – 90.3% in the first year of ART and 46% – 85.4% after 2 years. 9 It 
is important to note that the proportion of ART naïve patients who are LTFU during the first 
year of ART initiation is 3 fold higher in low income settings than in rich countries. 10 On 
the other hand, literature shows that LTFU rates among patients on TB treatment eligible for 
ART are around 11.0% in South Africa.11 These patients were LTFU approximately 2 
months after commencing TB treatment. 11 Furthermore, not presenting for ART assessment 
and not being initiated on ART were risk factors associated with LTFU among TB 
patients 11. Studies and systematic reviews have described LTFU and mortality among 
patients attending HIV care services. 9,12,13 However, data on patients co-treated for TB and 
HIV is still limited.
The aim of the study was to evaluate the effect of early integrated, late integrated and 
delayed ART initiation during TB treatment on incidence rates of LTFU and to evaluate the 
effect of ART initiation on LTFU rates within trial arms in patients co-infected with TB and 
HIV. We report incidence and predictors of LTFU at different follow-up time points in a 
randomised controlled clinical trial.
 METHODS
 Study population
The study design and the results of the Starting Antiretroviral Therapy at Three Points in 
Tuberculosis (SAPiT) trial have been published in detail elsewhere. 8,14,15 Briefly, the study 
was a three-armed open label, randomised, controlled trial conducted between June 2005 
and July 2010 to determine the optimal timing of ART initiation in newly diagnosed patients 
with HIV and smear positive pulmonary tuberculosis. At TB treatment initiation, ART naïve 
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patients were randomly assigned to initiate ART within 4 weeks of tuberculosis treatment 
initiation (early integrated arm), within 4 weeks after completion of the intensive phase of 
tuberculosis treatment (late integrated arm) or within 4 weeks after completion of 
tuberculosis therapy (sequential arm). Patients accessed routine TB services from the 
adjacent large outpatient government supported TB facility. Patients accessed HIV care at 
the CAPRISA treatment research clinic, where counselling, adherence assessments and 
clinical toxicity monitoring for both TB and HIV treatment also occurred.
Patients who missed scheduled monthly visits were tracked telephonically and if that failed 
then they were physically tracked. LTFU was defined as having missed 4 consecutive 
monthly visits with the inability to establish any contact with the patient. Post study exit, the 
South African Department of Home Affairs system was used to ascertain whether LTFU 
patients were currently dead or alive.
The SAPIT study was approved by the Biomedical Research Ethics Committee of the 
University of KwaZulu-Natal (E107/05) and the Medicines Control Council of South Africa 
(20060157).
 Data analysis
Follow-up time was calculated from TB treatment initiation until the earliest of: last visit 
date for those who were LTFU, date of death, termination date or administrative censoring at 
24 months. In the results published previously, 8,14,15 administrative censoring took place at 
18 months post TB treatment initiation but in this analysis administrative censoring was at 
24 months. Analysis was conducted at different follow-up times namely: during TB 
treatment, after the completion of TB treatment, before and after ART initiation as well as at 
24 months post TB treatment initiation.
Multivariate proportional hazards regression models were used to identify predictors of 
LTFU at different follow-up time points. Baseline variables that were included in the 
multivariate analysis were: trial arm, age, gender, WHO stage of HIV disease, CD4+ cell 
count, presence or absence of history of TB and employment status. We used Poisson 
approximations to calculate 95% confidence interval (CI) for incidence rates and incidence 
rate ratio (IRR). Proportionality was tested by fitting the time dependent covariates created 
by interacting the baseline variables and a function of survival time. Statistical analyses were 
done using Statistical Analysis Software version 9.3 (SAS Institute, Cary, North Carolina, 
USA).
 RESULTS
 Patients’ characteristics
A total of 642 patients were randomised (Figure 1). Patients in the early integrated (n = 214), 
late integrated (n=215), and sequential (n =213) arms had similar baseline demographic and 
clinical characteristics. 15 Of the 642, 96 (15.0%) patients were LTFU, 26 (12.1%) in the 
early integrated, 36 (16.7%) in the late integrated and 34 (16.0%) in the sequential arm. 
Notably, the proportion of patients who were LTFU in this study was higher than the overall 
mortality of 10.7% (69/642). The proportion of patients LTFU before and after ART 
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initiation was 9.2% (59/642) and 5.8% (37/642) respectively. LTFU among the 96 patients 
occurred at a median of 6.0 (interquartile range (IQR): 1.1 to 11.3) months after TB 
treatment initiation. LTFU before and after ART initiation occurred 2.8 (IQR: 0.5 to 6.7) and 
10.4 (IQR: 6.2 to 15.7) months after TB treatment initiation. The mean duration on TB 
treatment was 7.1 months. The mean duration by trial arm was 7.3, 7.1 and 6.9 months in the 
early integrated, late integrated and sequential arm respectively. Of the 96 LTFU, 64.6% 
(62/96) were LTFU during TB treatment while 35.4% (34/96) were LTFU after completing 
TB treatment (Figure 1).
Vital status for 88 of the 96 patients that were LTFU was obtained, 8 could not be traced 
(three in the early integrated arm, four in the late integrated arm and one in the sequential 
arm) due to missing identity numbers. 31.8% (28/88) were confirmed dead (four in the early 
integrated arm, 10 in the late integrated arm and 14 in the sequential arm), 68.2% (60/88) 
were still alive (19 in the early integrated arm, 22 in the late integrated arm and 19 in the 
sequential arm).
 Incidence of LTFU
Incidence rates of LTFU was 7.5 per 100 person-years (py) (95% confidence interval (CI), 
4.9 to 11), 10.9 per 100 py (95% CI, 7.6 to 15.1) and 11.0 per 100 py (95% CI, 7.6 to 15.4) 
in the early integrated, late integrated and sequential arm (p=0.313) (Table 1, Figure 2).
Incidence rate of LTFU before and after ART initiation was 31.7 per 100 py (95% CI, 11.6 
to 69.0) vs. 6.1 per 100 py (95% CI, 3.7 to 9.4), IRR: 5.2 (95% CI, 2.1 to 13.0), p<0.001 in 
the early integrated arm; 31.9 per 100 py (95% CI, 20.4 to 47.5) vs. 4.7 per 100 py (95% CI, 
2.4 to 8.2), IRR: 6.8 (95% CI, 3.4 to 13.6), p<0.0001 in the late integrated arm and 21.9 per 
100 py (95% CI, 14.6 to 31.5) vs. 2.8 (95% CI: 0.9 to 6.6) per 100 py, IRR: 7.7 (95% CI: 3.0 
to 19.9), p<0.0001 in the sequential arm (Table 1).
The overall incidence rate of LTFU at 24 months post TB treatment initiation was 9.8 per 
100 py (95% CI, 7.9 to 11.9).
The incidence rates for all other follow-up time points are shown in Table 1. Combining the 
3 trial arms together, the incidence rate of LTFU was higher during TB treatment and 
declined thereafter: from 16.3 per 100 py (95%CI, 12.5 to 20.9) to 5.6 per 100 py (95% CI, 
3.9 to 7.9) (p < 0.001). The same trend was observed within each trial arm. Incidence rate of 
LTFU during and after TB treatment completion was 10.9 per 100 py (95% CI, 5.9 to 18.3) 
vs. 5.5 per 100 py (95% CI, 2.9 to 9.7), IRR: 2.0 (95% CI, 0.9 to 4.3), p=0.085 in the early 
integrated arm; 19.0 per 100 py (95% CI, 12.1 to 28.2) vs. 5.9 per 100 py (95% CI: 3.0 to 
10.3), IRR: 3.2 (95% CI, 1.6 to 6.4), p=0.001 in the late integrated arm and 19.1 per 100 py 
(95% CI, 12.2 to 28.4) vs. 5.5 per 100 py (95% CI, 2.6 to 10.1), IRR: 3.5 (95% CI, 1.7 to 
7.3), p=0.001 in the sequential arm (Table 1).
 Risk factors associated with LTFU
In an adjusted analysis, gender (male vs. female) was a significant predictor of LTFU during 
TB treatment (HR: 1.8; 95% CI: 1.03 to 3.1), after TB treatment (HR: 2.4; 95% CI: 1.1 to 
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5.0), before ART initiation (HR: 1.9; 95% CI: 1.1 to 3.3) and at 24 months post TB 
treatment initiation (HR: 1.9; 95% CI: 1.2 to 3.0).
Age (per 5 year increase) was a significant predictor of LTFU during TB treatment (HR: 0.8; 
95% CI: 0.6 to 0.9), before ART initiation (HR: 0.7; 95% CI: 0.6 to 0.9), and at 24 months 
post TB treatment initiation (HR: 0.8; 95% CI: 0.7 to 0.9). Employment status (employed vs. 
unemployed) was also associated with LTFU after TB treatment (HR: 0.3; 95% CI: 0.1 to 
0.6) whereas CD4+ count at baseline (<200 vs. >350 cells/mm3) was a significant predictor 
of LTFU at 24 months post TB treatment initiation (HR: 0.6; 95% CI: 0.3 to 0.99) (Table 2). 
In addition, patients who were LTFU had higher mean CD4+ count over time than those 
who were not LTFU (Figure S1).
 DISCUSSION
The incidence rates of LTFU was not significantly different across the three trial arms. 
However, we report dramatically reduced LTFU rates among TB patients initiating ART 
compared to those not initiating ART within each trial arm (Table 1). In this paper we 
provide evidence demonstrating further benefit of initiating ART during TB treatment at 
both an individual patient level and at a TB control programme level. We demonstrated 5.2; 
6.8 and 7.7 fold higher rates of LTFU before ART initiation compared to after ART initiation 
in the early integrated, late integrated and sequential arms respectively. The median time to 
LTFU among patients not initiated on ART was 2.8 (IQR: 0.5 to 6.7) months. This increases 
the strength of the World Health Organisation (WHO) recommendation of initiating ART 
within the first eight weeks of TB treatment, 16 as this not only provides a survival benefit it 
also confers a programmatic benefit of reducing LTFU. Data to date have suggested that 
integrating TB and HIV may undermine the TB control program through issues of increase 
pill burden and programmatic challenges of co-managing both diseases. 17 However, the risk 
of increased mortality from not initiating ART timeously in TB patients has been shown. 8
Despite being enrolled for TB services, we found that the majority of retention losses 
occurred among TB patients that had not yet initiated ART. Furthermore, an observational 
study conducted on ART eligible patients in South Africa showed LTFU rates of 
approximately 10%, among newly-diagnosed TB patients and in those already on TB 
treatment at study entry. The pre-ART LTFU seen in our study is very similar to rates seen 
elsewhere in sub-Saharan Africa, 13 where up to 69% of patients did not return to the clinic 
within 1 year of enrolment. 18 The TB programmes in Africa are also affected with higher 
pre-TB treatment LTFU, with rates ranging from 6% to 38% among smear or culture 
positive tuberculosis. 19 Our data highlights the wider benefit of ART initiation during TB 
treatment and underscores the need for implementing retention strategies in pre-ART care 
especially in TB and HIV endemic settings.
While ART scale up in South Africa has successfully reduced AIDS related mortality, LTFU 
within the ART programme has increased substantially. 20 These data add to the pool of data 
suggesting that LTFU masks mortality. We found almost a third (29.2%) of the 96 patients 
initially deemed LTFU, were later confirmed dead. This and several other studies have 
showed that the mortality rate among LTFU patients is much higher than among patients 
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remaining in care. 21 While we are unsure whether these deaths occurred early or late in the 
TB program, it highlights the need for effective retention strategies and seamless linkage to 
services especially for TB HIV co-infected patients and for those with advanced 
immunosuppression who are at higher risk for mortality.
Published studies evaluating LTFU cite patient transfer to nearby clinics, financial difficulty, 
improved or deteriorating health21–24, and mortality in about 20% to 60% of patients as the 
most common reasons for LTFU. 21,24–26 This study identified several factors that were 
associated with LTFU in Table 2. Trial arm, age, gender, CD4+ count and employment status 
were significant predictors of LTFU at different follow-up time points. Males and younger 
patients were consistently at high risk of being LTFU in most follow-up time points. 
Consistent with previous publications,20,27–30 females and older patients were less likely to 
be LTFU. Unemployment has been associated with higher risk of LTFU during TB 
treatment. 27
However, we found that unemployment was associated with higher risk of LTFU after TB 
treatment completion. Unemployed patients possibly relocated to other cities to look for 
employment. Clinic operating hours and finding new employment were cited as the reason 
for defaulting, 31 therefore it might be difficult for patients to ask the new employer for time 
off work every month to go to the clinic or hospital. Therefore, Saturday clinics or adjusted 
clinic hours might be a solution to provide support for such patients.
The risk of being LTFU in our study was higher among patients with high CD4+ cell count. 
We showed that patients with baseline CD4+ cell count <200 cells/mm3 were less likely to 
be LTFU than those with CD4+ cell count >350 cells/mm3. Also, LTFU patients had higher 
CD4+ count over time compared to those who were not LTFU (Figure S1). In agreement, 
studies conducted in South Africa 6,18 and another in France 32 showed patients who were 
LTFU either in the pre-ART care or care after ART had high baseline CD4+ count.
In contrast, other studies of patients on ART have shown that patients with low baseline 
CD4+ count are more likely to be LTFU than those with high CD4+ cell count 20,30,33. As 
the widespread use of ART increases as well as an increased in CD4+ count threshold for 
ART initiation, more patients are likely to initiate ART at higher CD4+ counts and be 
managed in ART programmes for longer.34–36 Within a context of high risk of mortality 
irrespective of pre-ART CD4+ counts in TB-HIV co-infected patients, a stringent tracing 
system should be implemented to address LTFU in both TB and HIV programmes among all 
patients irrespective of CD4+ cell count. Moreover, digital systems that enable patient 
referral, transfer between facilities and linkage to a national death registry is essential to 
programmatically address and manage LTFU in TB and ART programs.
 Limitations
We acknowledge several limitations. The study was not powered for the LTFU outcome. The 
reasons for LTFU could not be ascertained due to patients providing unreliable addresses, 
prepaid mobile phone numbers which are changed repeatedly and some patients migrated to 
other cities after feeling better. We might have overestimated or underestimated the impact 
of mortality in patients that were LTFU because eight patients had missing vital status. 
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Follow-up in this study was 24 months, we have no data beyond 24 months to report on long 
term LTFU rates within programmes. Therefore our study findings are not generalizable 
beyond 24 months post TB treatment initiation. In addition, these findings may also not be 
generalizable to patients with multidrug resistant TB and extra pulmonary TB who are likely 
to be sicker, take longer and more complex treatment regimen.
 CONCLUSION
LTFU rates were not significantly different between the three trials arms. However, ART 
initiation within each trial arm resulted in a significant reduction in LTFU rates among TB 
and HIV co-infected patients.
The incidence rate of LTFU was higher among TB patients not initiated on ART and also 
higher during the course of TB treatment. Trial arm, age, gender, CD4+ cell count and 
employment status were associated with LTFU at different follow-up time points.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
SAPiT trial: Screening, randomization, and follow-up of study patients demonstrating loss to 
follow-up
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Figure 2. 
Kaplan–Meier estimates of cumulative probability of being LTFU.
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